BFRG BULLFROG AI HOLDINGS

BullFrog AI to Showcase AI-Powered Clinical Data Solutions in Xtalks Webinar

BullFrog AI to Showcase AI-Powered Clinical Data Solutions in Xtalks Webinar

GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, that its Director of AI, Machine Learning & Innovation, Juan Felipe Beltrán Lacouture, PhD, will present a hosted by Xtalks titled “Clinical Data Analysis with Agents: Reliable Automation with Human Oversight.” The webinar will take place on Monday, October 6, 2025, at 11:00 am EDT (5:00 pm CEST).

Advancing Reliable Automation with Human Oversight

During the webinar, Dr. Beltrán will share how BullFrog AI’s proprietary platforms, bfPREP™ and bfLEAP™, were used to transform more than 10,000 pages of unstructured clinical PDFs into an OMOP-structured dataset suitable for advanced analysis and machine learning.

The presentation will provide attendees with a practical framework for:

  • Leveraging bfPREP™ to parse, triage, and extract data from complex clinical documents.
  • Aligning extracted concepts to standardized vocabularies such as SNOMED CT, RxNorm, and LOINC through human-in-the-loop validation.
  • Applying template-driven agents to edit schema-constrained loaders and transformation snippets for OMOP tables.
  • Extending verified data pipelines with feature engineering for disease categorization, medication normalization, and other clinical insights.

The session will highlight how BullFrog AI balances the speed of agent-driven automation with the safety, nuance, and oversight of human expertise, ensuring trustworthy, auditable, and efficient clinical data pipelines.

A Practical, Real-World Approach

Attendees will also learn how BullFrog AI identified and mitigated common intake failure modes, including clipped layouts and column ambiguities, while maintaining strong data integrity. The goal is not full automation, but verified automation, a method that accelerates clinical research workflows without sacrificing human judgment or quality control.

“BullFrog AI is committed to advancing data integrity and reliability in the drug development process,” said Vin Singh, Founder and CEO of BullFrog AI. “This webinar demonstrates how our technologies deliver practical, safe, and scalable solutions that enable researchers to make better, faster decisions with confidence.”

Event Details

  • Title: Clinical Data Analysis with Agents: Reliable Automation with Human Oversight
  • Date: Monday, October 6, 2025
  • Time: 11:00 am EDT (5:00 pm CEST)
  • Presenter: Juan Felipe Beltrán Lacouture, PhD, Director of AI, Machine Learning & Innovation, BullFrog AI

To register, visit: .

About BullFrog AI

BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.

For more information visit BullFrog AI at:

About Xtalks

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit

For information about hosting a webinar, visit

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," “could,” “will,” "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™ and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Dave Gentry

RedChip Companies, Inc.

1-407-644-4256



EN
23/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BULLFROG AI HOLDINGS

 PRESS RELEASE

BullFrog AI to Showcase AI-Powered Clinical Data Solutions in Xtalks W...

BullFrog AI to Showcase AI-Powered Clinical Data Solutions in Xtalks Webinar GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, that its Director of AI, Machine Learning & Innovation, Juan Felipe Beltrán Lacouture, PhD, will present a hosted by Xtalks titled “Clinical Data Analysis with Agents: Reliable Automation with Human Oversight.” The webinar will tak...

 PRESS RELEASE

BullFrog AI’s bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact ...

BullFrog AI’s bfPREP™ and bfLEAP® Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration Joint oncology conference submission planned and follow-on contract discussion underway Validates BullFrog AI’s enterprise-grade platform strategy, combining automation and human-in-the-loop oversight for scalable, trustworthy analytics GAITHERSBURG, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful ...

 PRESS RELEASE

BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference

BullFrog AI to Present at BTIG Annual Virtual Biotechnology Conference GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, CEO, will participate in a fireside chat and one-on-one meetings at BTIG’s Annual Virtual Biotechnology Conference, being held Tuesday, July 29 through Wednesday, July 30. Fireside Presentation De...

 PRESS RELEASE

Rethinking R&D: BullFrog AI White Paper Outlines New Blueprint for Sma...

Rethinking R&D: BullFrog AI White Paper Outlines New Blueprint for Smarter Drug Development From target discovery to trial optimization, bfLEAP™ empowers biopharma teams to predict therapeutic success with greater confidence In a $200B+ market crowded with black-box AI, BullFrog AI’s bfLEAP™ delivers what others can’t: biologically grounded, composition-aware analytics that guide smarter therapeutic decisions GAITHERSBURG, Md., July 22, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial int...

 PRESS RELEASE

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on ...

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on July 23 GAITHERSBURG, Md., July 18, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics,, is pleased to invite investors to a webinar on July 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature BullFrog AI’s Founder and CEO, Vin Singh. Attendees will gain insights into BullFrog AI’...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch